Related Experiment Videos
[Cyclosporin therapy for idiopathic thrombocytopenic purpura]
A Sasaki1, T Inoue, Y Furukawa
1Clinical Laboratory Medicine, Osaka City University Medical School.
Insights
Cyclosporin treatment for chronic idiopathic thrombocytopenic purpura (ITP) showed promising results. In a study of nine patients, platelet counts increased, suggesting cyclosporin may benefit refractory ITP cases.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Context:
- Chronic idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts.
- Current treatments for refractory ITP have limitations, necessitating exploration of alternative therapies.
Purpose:
- To evaluate the efficacy and safety of cyclosporin in adult patients with chronic refractory idiopathic thrombocytopenic purpura.
Summary:
- Nine adult patients with chronic ITP and platelet counts below 5 x 10(4)/microliters received oral cyclosporin (5 mg/kg/day) for 8 weeks.
- One patient achieved platelet counts over 10 x 10(4)/microliters, and four patients exceeded 5 x 10(4)/microliters.
- Gingival hyperplasia occurred in one patient; no renal dysfunction was observed. Platelet-associated IgG (PAIgG) levels declined.
Impact:
- Cyclosporin demonstrated a potential therapeutic benefit in refractory ITP, with notable improvements in platelet counts.
- The observed decline in PAIgG suggests an immunomodulatory effect contributing to treatment efficacy.
- Further research is warranted to establish cyclosporin as a viable treatment option for refractory ITP.
Abstract:
Nine adult patients with chronic idiopathic thrombocytopenic purpura (ITP) were treated with cyclosporin. Their platelet counts were all below 5 x 10(4)/microliters. It was administered orally at 5 mg/kg/day for 8 weeks. In one patient, the platelet count increased over 10 x 10(4)/microliters in 4 patients it did over 5 x 10(4)/microliters. Gingival hyperplasia was observed in one patient. Renal dysfunction was not observed in any patients. The elevation of PAIgG declined during the period of treatment. These results suggest that this therapy may be useful in refractory idiopathic thrombocytopenic purpura.